Top Industry Leaders in the LDL Test Market
Numares Health Received FDA clearance for their AXINON® LDL-p Test System, the first commercially available NMR test for measuring LDL-p (particle number), considered a more accurate indicator of cardiovascular risk than traditional LDL-C (concentration).
Roche (OTCQX: RHHBY) Introduced the Elecsys Total Cholesterol assay, a highly accurate and rapid test for measuring total cholesterol levels directly from fingerstick blood samples.
Abbott (NYSE: ABT) Expanded the FreeStyle Libre 3 system to include cholesterol monitoring alongside glucose, offering a combined solution for managing metabolic health.
Verve Therapeutics Initiated Phase 3 trial for their investigational gene therapy, VERVE-AL001, aiming to significantly reduce LDL cholesterol levels and potentially revolutionize lipid management.
Akero Therapeutics Announced promising early data from their Phase 2a trial for AKR-001, a novel oral therapy targeting CETP for lowering LDL cholesterol and raising HDL cholesterol.
Aegerion Pharmaceuticals Presented positive Phase 2b data for their APOC3 antisense oligonucleotide drug, IONIS-APO-C3-LRx, demonstrating significant reductions in triglyceride and LDL levels.
List of LDL Test Key Companies in the Market
- Quest Diagnostics Incorporated
- Sekisui Diagnostics
- Express Biotech International
- Randox Laboratories Ltd
- Reckon Diagnostics
- DiaSys Diagnostics India Private Limited
- Hoffmann-La Roche Ltd